{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T09:50:08Z","timestamp":1790675408150,"version":"4.1.0"},"reference-count":50,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,3,30]],"date-time":"2023-03-30T00:00:00Z","timestamp":1680134400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["K23DA042326"],"award-info":[{"award-number":["K23DA042326"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["K23DA044874"],"award-info":[{"award-number":["K23DA044874"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R44DA051106"],"award-info":[{"award-number":["R44DA051106"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000185","name":"Defense Advanced Research Projects Agency","doi-asserted-by":"publisher","award":["HR001120S0041"],"award-info":[{"award-number":["HR001120S0041"]}],"id":[{"id":"10.13039\/100000185","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Psychiatry"],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Opioid use disorder (OUD) continues to be a significant public health concern. Medications for OUD (MOUD) such as buprenorphine reduce overdose mortality, but relapses occur often, leading to adverse outcomes. Preliminary data suggest that cannabidiol (CBD) may be a potential adjunctive treatment to MOUD by attenuating cue-reactivity. This pilot study sought to evaluate the impact of a single dose of CBD on reward- and stress-related neurocognitive processes implicated in relapse among those with OUD.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The study was a pilot, double-blind, placebo-controlled, randomized cross-over trial aimed at assessing the effects of a single dose of CBD (Epidiolex\u00ae) 600\u2009mg or matching placebo administered to participants with OUD receiving either buprenorphine or methadone. Vital signs, mood states, pain, opioid withdrawal, cue-induced craving, attentional bias, decision-making, delayed discount, distress tolerance, and stress-reactivity were examined at each testing session on two separate testing days at least 1 week apart.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Ten participants completed all study procedures. Receipt of CBD was associated with a significant decrease in cue-induced craving (0.2 vs. 1.3, <jats:italic>p<\/jats:italic> =\u20090.040), as well as reduced attentional bias toward drug-related cues as measured by the visual probe task (\u221280.4 vs. 100.3, <jats:italic>p<\/jats:italic> =\u20090.041). No differences were found among all the other outcomes examined.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>CBD may have promise as an adjunct to MOUD treatment by attenuating the brain response to drug-related cues, which, in turn, may reduce the risk of relapse and overdoses. Further research is warranted to evaluate the potential for CBD as an adjunctive therapy for individuals in treatment for OUD.<\/jats:p><\/jats:sec><jats:sec><jats:title>Clinical Trial Registration<\/jats:title><jats:p><jats:ext-link>https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04982029<\/jats:ext-link>.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fpsyt.2023.1155984","type":"journal-article","created":{"date-parts":[[2023,3,30]],"date-time":"2023-03-30T11:24:06Z","timestamp":1680175446000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":15,"title":["Impact of cannabidiol on reward- and stress-related neurocognitive processes among individuals with opioid use disorder: A pilot, double-blind, placebo-controlled, randomized cross-over trial"],"prefix":"10.3389","volume":"14","author":[{"given":"Joji","family":"Suzuki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Prostko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica","family":"Szpak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter R.","family":"Chai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Primavera A.","family":"Spagnolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth E.","family":"Tenenbaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saeed","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger D.","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,3,30]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"202","DOI":"10.15585\/mmwr.mm7006a4","article-title":"Trends and geographic patterns in drug and synthetic opioid overdose deaths \u2014 United States, 2013\u20132019","volume":"70","author":"Mattson","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"ref2","volume-title":"State unintentional drug overdose reporting system (SUDORS). [internet]","year":"2022"},{"key":"ref3","year":"2018"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1176\/appi.ps.201300235","article-title":"Medication-assisted treatment with methadone: assessing the evidence","volume":"65","author":"Fullerton","year":"2014","journal-title":"Psychiatr Serv"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"CD002207","DOI":"10.1002\/14651858.CD002207.pub4","article-title":"Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence","volume":"2","author":"Mattick","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"j1550","DOI":"10.1136\/bmj.j1550","article-title":"Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies","volume":"357","author":"Sordo","year":"2017","journal-title":"BMJ"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1080\/00952990.2018.1454933","article-title":"Using ecological momentary assessment to examine the relationship between craving and affect with opioid use in a clinical trial of clonidine as an adjunct medication to buprenorphine treatment","volume":"44","author":"Kowalczyk","year":"2018","journal-title":"Am J Drug Alcohol Abuse"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"108764","DOI":"10.1016\/j.drugalcdep.2021.108764","article-title":"Characterizing initiation, use, and discontinuation of extended-release buprenorphine in a nationally representative United States commercially insured cohort","volume":"225","author":"Morgan","year":"2021","journal-title":"Drug Alcohol Depend"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1038\/npp.2017.275","article-title":"Exacerbated craving in the presence of stress and drug cues in drug-dependent patients","volume":"43","author":"Preston","year":"2018","journal-title":"Neuropsychopharmacology"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1176\/appi.ajp.2016.16070792","article-title":"The role of behavioral interventions in buprenorphine maintenance treatment: a review","volume":"174","author":"Carroll","year":"2016","journal-title":"Am J Psychiatry"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.3390\/jcm8071058","article-title":"The potential of Cannabidiol as a treatment for psychosis and addiction: who benefits Most? A systematic review","volume":"8","author":"Batalla","year":"2019","journal-title":"J Clin Med"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.neuro.2019.08.002","article-title":"Cannabidiol (CBD) use in psychiatric disorders: a systematic review","volume":"74","author":"Bonaccorso","year":"2019","journal-title":"Neurotoxicology"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"63","DOI":"10.3389\/fpsyt.2019.00063","article-title":"The Endocannabinoid system and Cannabidiol\u2019s promise for the treatment of substance use disorder","volume":"10","author":"Chye","year":"2019","journal-title":"Front Psych"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"4790","DOI":"10.1111\/bph.13250","article-title":"Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor","volume":"172","author":"Laprairie","year":"2015","journal-title":"Br J Pharmacol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1111\/bph.12944","article-title":"Are cannabidiol and \u0394(9) -tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic review","volume":"172","author":"McPartland","year":"2015","journal-title":"Br J Pharmacol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"14764","DOI":"10.1523\/JNEUROSCI.4291-09.2009","article-title":"Cannabidiol, a nonpsychotropic component of cannabis, inhibits Cue-induced heroin seeking and normalizes discrete mesolimbic neuronal disturbances","volume":"29","author":"Ren","year":"2009","journal-title":"J Neurosci"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1038\/npp.2010.58","article-title":"Cannabidiol attenuates the appetitive effects of Delta 9-tetrahydrocannabinol in humans smoking their chosen cannabis","volume":"35","author":"Morgan","year":"2010","journal-title":"Neuropsychopharmacology"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1111\/add.14243","article-title":"Cannabidiol reverses attentional bias to cigarette cues in a human experimental model of tobacco withdrawal","volume":"113","author":"Hindocha","year":"2018","journal-title":"Addiction"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1089\/imr.2022.0070","article-title":"Cannabidiol effect on Cue-induced craving for individuals with opioid use disorder treated with buprenorphine: a small proof-of-concept open-label study","volume":"1","author":"Suzuki","year":"2022","journal-title":"Integr Med Rep"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1007\/s13311-015-0373-7","article-title":"Early phase in the development of Cannabidiol as a treatment for addiction: opioid relapse takes initial center stage","volume":"12","author":"Hurd","year":"2015","journal-title":"Neurotherapeutics"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1176\/appi.ajp.2019.18101191","article-title":"Cannabidiol for the reduction of Cue-induced craving and anxiety in drug-abstinent individuals with heroin use disorder: a double-blind randomized placebo-controlled trial","volume":"176","author":"Hurd","year":"2019","journal-title":"Am J Psychiatry"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/978-1-4612-0357-5_3","article-title":"Timeline follow-back: a technique for assessing self-reported ethanol consumption","volume-title":"Measuring alcohol consumption: Psychosocial and biological methods","author":"Sobell","year":"1992"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1046\/j.1525-1497.2001.016009606.x","article-title":"The PHQ-9: validity of a brief depression severity measure","volume":"16","author":"Kroenke","year":"2001","journal-title":"J Gen Intern Med"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1001\/archinte.166.10.1092","article-title":"A brief measure for assessing generalized anxiety disorder: the GAD-7","volume":"166","author":"Spitzer","year":"2006","journal-title":"Arch Intern Med"},{"key":"ref25","first-page":"129","article-title":"Pain assessment: global use of the brief pain inventory","volume":"23","author":"Cleeland","year":"1994","journal-title":"Ann Acad Med Singap"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1037\/0022-3514.54.6.1063","article-title":"Development and validation of brief measures of positive and negative affect: the PANAS scales","volume":"54","author":"Watson","year":"1988","journal-title":"J Pers Soc Psychol"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1080\/02791072.2003.10400007","article-title":"The clinical opiate withdrawal scale (COWS)","volume":"35","author":"Wesson","year":"2003","journal-title":"J Psychoactive Drugs"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1111\/j.1521-0391.2014.12129.x","article-title":"Cue-induced craving in dependence upon prescription opioids and heroin","volume":"23","author":"McHugh","year":"2014","journal-title":"Am J Addict"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1111\/ajad.12344","article-title":"Cue-induced craving to paraphernalia and drug images in opioid dependence","volume":"25","author":"McHugh","year":"2016","journal-title":"Am J Addict"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.drugalcdep.2008.03.030","article-title":"Attentional bias in addictive behaviors: a review of its development, causes, and consequences","volume":"97","author":"Field","year":"2008","journal-title":"Drug Alcohol Depend"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1111\/j.1360-0443.2003.00669.x","article-title":"Heroin and cocaine abusers have higher discount rates for delayed rewards than alcoholics or non-drug-using controls","volume":"99","author":"Kirby","year":"2004","journal-title":"Addiction"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/0010-0277(94)90018-3","article-title":"Insensitivity to future consequences following damage to human prefrontal cortex","volume":"50","author":"Bechara","year":"1994","journal-title":"Cognition"},{"key":"ref33","first-page":"1229","volume-title":"J Atten Disord","author":"Seymour","year":"2019"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1037\/hea0000862","article-title":"Behavioral strategies to reduce stress reactivity in opioid use disorder: study design","volume":"39","author":"McHugh","year":"2020","journal-title":"Health Psychol"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"108755","DOI":"10.1016\/j.drugalcdep.2021.108755","article-title":"Laboratory-induced stress and craving predict opioid use during follow-up among individuals with prescription opioid use disorder","volume":"225","author":"Saraiya","year":"2021","journal-title":"Drug Alcohol Depend"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2019.00592","article-title":"Craving in opioid use disorder: from neurobiology to clinical practice","volume":"10","author":"Kakko","year":"2019","journal-title":"Front Psych"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"3685","DOI":"10.1007\/s00213-015-4027-6","article-title":"Cue reactivity and its relation to craving and relapse in alcohol dependence: a combined laboratory and field study","volume":"232","author":"Witteman","year":"2015","journal-title":"Psychopharmacology"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"e186466","DOI":"10.1001\/jamanetworkopen.2018.6466","article-title":"Association of Neural Responses to drug cues with subsequent relapse to stimulant use","volume":"1","author":"MacNiven","year":"2018","journal-title":"JAMA Netw Open"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1152\/physrev.00014.2018","article-title":"The neuroscience of drug reward and addiction","volume":"99","author":"Volkow","year":"2019","journal-title":"Physiol Rev"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"2713","DOI":"10.1007\/s00213-018-4966-9","article-title":"Before and after: craving, mood, and background stress in the hours surrounding drug use and stressful events in patients with opioid-use disorder","volume":"235","author":"Preston","year":"2018","journal-title":"Psychopharmacology"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1017\/S1092852913000321","article-title":"The clinical relevance of attentional bias in substance use disorders","volume":"19","author":"Field","year":"2014","journal-title":"CNS Spectr"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.cobeha.2018.01.007","article-title":"Current perspectives on incentive salience and applications to clinical disorders","volume":"22","author":"Olney","year":"2018","journal-title":"Curr Opin Behav Sci"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1038\/npp.2011.6","article-title":"Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-na\u00efve social phobia patients","volume":"36","author":"Bergamaschi","year":"2011","journal-title":"Neuropsychopharmacology"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"5852","DOI":"10.3390\/jcm10245852","article-title":"Enhancing Endocannabinoid control of stress with Cannabidiol","volume":"10","author":"Henson","year":"2021","journal-title":"J Clin Med"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1007\/s13311-015-0387-1","article-title":"Cannabidiol as a potential treatment for anxiety disorders","volume":"12","author":"Blessing","year":"2015","journal-title":"Neurotherapeutics"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.drugalcdep.2015.08.019","article-title":"Laboratory-induced stress and craving among individuals with prescription opioid dependence","volume":"155","author":"Back","year":"2015","journal-title":"Drug Alcohol Depend"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1177\/1529100619860513","article-title":"A neurobehavioral approach to addiction: implications for the opioid epidemic and the psychology of addiction","volume":"20","author":"Bechara","year":"2019","journal-title":"Psychol Sci Public Interest"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1037\/0096-3445.128.1.78","article-title":"Heroin addicts have higher discount rates for delayed rewards than non-drug-using controls","volume":"128","author":"Kirby","year":"1999","journal-title":"J Exp Psychol Gen"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"e0181955","DOI":"10.1371\/journal.pone.0181955","article-title":"Intolerance of uncertainty in opioid dependency\u2014relationship with trait anxiety and impulsivity","volume":"12","author":"Garami","year":"2017","journal-title":"PLoS One"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.drugalcdep.2014.11.007","article-title":"A preliminary randomized controlled trial of a distress tolerance treatment for opioid dependent persons initiating buprenorphine","volume":"147","author":"Stein","year":"2015","journal-title":"Drug Alcohol Depend"}],"container-title":["Frontiers in Psychiatry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2023.1155984\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,30]],"date-time":"2023-03-30T11:24:10Z","timestamp":1680175450000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2023.1155984\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,30]]},"references-count":50,"alternative-id":["10.3389\/fpsyt.2023.1155984"],"URL":"https:\/\/doi.org\/10.3389\/fpsyt.2023.1155984","relation":{},"ISSN":["1664-0640"],"issn-type":[{"value":"1664-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,30]]},"article-number":"1155984"}}